Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 10-21 , January 2007

Endoscopic Therapy of Dysplasia and Early-Stage Cancers of the Esophagus

References 

  1. Stathopoulos GP, Tsiaras N. Epidemiology and pathogenesis of esophageal cancer: Management and its controversial results (review). Oncol Rep. 2003;10:449–454
  2. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  3. Shaheen NJ. Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128:1554–1566
  4. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888–1895
  5. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  6. Lieberman DA, Oehlke M, Helfand M Gastroenterology Outcomes Research Group in Endoscopy. Risk factors for Barrett’s esophagus in community-based practice (GORGE consortium). Am J Gastroenterol. 1997;92:1293–1297
  7. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290:66–72
  8. Nilsson M, Johnsen R, Ye W, et al. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut. 2004;53:1730–1735
  9. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–1413
  10. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis. 1976;21:953–956
  11. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus (A prevalent, occult complication of gastroesophageal reflux disease). Gastroenterology. 1987;92:118–124
  12. Chow WH, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995;274:474–477
  13. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: Is it cost-effective?. Am J Gastroenterol. 2000;95:2086–2093
  14. Canto MI. Chromoendoscopy and magnifying endoscopy for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2005;3(suppl 1):S12–S15
  15. Canto MI, Setrakian S, Willis J, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2000;51:560–568
  16. Guelrud M, Herrera I, Essenfeld H, et al. Enhanced magnification endoscopy: A new technique to identify specialized intestinal metaplasia in Barrett’s esophagus. Gastrointest Endosc. 2001;53:559–565
  17. Sharma P, Sidorenko EI. Are screening and surveillance for Barrett’s oesophagus really worthwhile?. Gut. 2005;54(suppl 1):i27–i32
  18. Theisen J, Nigro JJ, DeMeester TR, et al. Chronology of the Barrett’s metaplasia-dysplasia-carcinoma sequence. Dis Esophagus. 2004;17:67–70
  19. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212–215
  20. Dulai GS, Shekelle PG, Jensen DM, et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett’s cohort. Am J Gastroenterol. 2005;100:775–783
  21. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?. Gastroenterology. 2000;119:333–338
  22. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett’s esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249–1256
  23. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109:1541–1546
  24. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931–968
  25. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988;19:166–178
  26. Haggitt RC. Barrett’s esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982–993
  27. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–255
  28. Spechler SJ. Dysplasia in Barrett’s esophagus: Limitations of current management strategies. Am J Gastroenterol. 2005;100:927–935
  29. Rice TW, Falk GW, Achkar E, et al. Surgical management of high-grade dysplasia in Barrett’s esophagus. Am J Gastroenterol. 1993;88:1832–1836
  30. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619
  31. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120:1630–1639
  32. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95:3383–3387
  33. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: Immunohistochemical marker predictive of progression. Am J Gastroenterol. 2001;96:1355–1362
  34. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000;95:1888–1893
  35. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett’s esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669–1676
  36. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379–388
  37. Dar MS, Goldblum JR, Rice TW, et al. Can extent of high grade dysplasia in Barrett’s oesophagus predict the presence of adenocarcinoma at oesophagectomy?. Gut. 2003;52:486–489
  38. Thomas P, Doddoli C, Neville P, et al. Esophageal cancer resection in the elderly. Eur J Cardiothorac Surg. 1996;10:941–946
  39. Stein HJ, Feith M, Mueller J, et al. Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg. 2000;232:733–742
  40. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–1666
  41. Holscher AH, Bollschweiler E, Schneider PM, et al. Early adenocarcinoma in Barrett’s oesophagus. Br J Surg. 1997;84:1470–1473
  42. Heitmiller RF, Redmond M, Hamilton SR. Barrett’s esophagus with high-grade dysplasia (An indication for prophylactic esophagectomy). Ann Surg. 1996;224:66–71
  43. Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000;119:1126–1132
  44. van Lanschot JJ, Hulscher JB, Buskens CJ, et al. Hospital volume and hospital mortality for esophagectomy. Cancer. 2001;91:1574–1578
  45. Dimick JB, Cattaneo SM, Lipsett PA, et al. Hospital volume is related to clinical and economic outcomes of esophageal resection in Maryland. Ann Thorac Surg. 2001;72:334–339discussion 339-341
  46. Begg CB, Cramer LD, Hoskins WJ, et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998;280:1747–1751
  47. Makuuchi H. Endoscopic mucosal resection for mucosal cancer in the esophagus. Gastrointest Endosc Clin North Am. 2001;11:445–458
  48. Johnston MH. Technology insight: ablative techniques for Barrett’s esophagus—Current and emerging trends. Nat Clin Pract Gastroenterol Hepatol. 2005;2:323–330
  49. Ackroyd R, Brown NJ, Stephenson TJ, et al. Ablation treatment for Barrett oesophagus: What depth of tissue destruction is needed?. J Clin Pathol. 1999;52:509–512
  50. Barr H, Stone N, Rembacken B. Endoscopic therapy for Barrett’s oesophagus. Gut. 2005;54:875–884
  51. Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: Implications for therapy. J Thorac Cardiovasc Surg. 1999;117:16–23discussion 23-25
  52. Fujita H, Sueyoshi S, Yamana H, et al. Optimum treatment strategy for superficial esophageal cancer: Endoscopic mucosal resection versus radical esophagectomy. World J Surg. 2001;25:424–431
  53. Wang KK, Sampliner RE. Mucosal ablation therapy of barrett esophagus. Mayo Clin Proc. 2001;76:433–437
  54. Barberi-Heyob M, Vedrine PO, Merlin JL, et al. Wild-type p53 gene transfer into mutated p53 HT29 cells improves sensitivity to photodynamic therapy via induction of apoptosis. Int J Oncol. 2004;24:951–958
  55. Heinzelmann-Schwarz V, Fedier A, Hornung R, et al. Role of p53 and ATM in photodynamic therapy-induced apoptosis. Lasers Surg Med. 2003;33:182–189
  56. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett’s esophagus: Follow-up in 100 patients. Gastrointest Endosc. 1999;49:1–7
  57. Ban S, Mino M, Nishioka NS, et al. Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett’s esophagus. Am J Surg Pathol. 2004;28:1466–1473
  58. Hage M, Siersema PD, Vissers KJ, et al. Genomic analysis of Barrett’s esophagus after ablative therapy: Persistence of genetic alterations at tumor suppressor loci. Int J Cancer. 2006;118:155–160
  59. Inoue H, Tani M, Nagai K, et al. Treatment of esophageal and gastric tumors. Endoscopy. 1999;31:47–55
  60. Takeshita K, Tani M, Inoue H, et al. Endoscopic treatment of early oesophageal or gastric cancer. Gut. 1997;40:123–127
  61. Inoue H. Endoscopic mucosal resection for the entire gastrointestinal mucosal lesions. Gastrointest Endosc Clin North Am. 2001;11:459–478
  62. Soetikno RM, Gotoda T, Nakanishi Y, et al. Endoscopic mucosal resection. Gastrointest Endosc. 2003;57:567–579
  63. Miyamoto S, Muto M, Hamamoto Y, et al. A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc. 2002;55:576–581
  64. Rosch T, Sarbia M, Schumacher B, et al. Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy. 2004;36(9):788–801
  65. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2000;118:670–677
  66. May A, Gossner L, Behrens A, et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc. 2003;58:167–175
  67. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia withing Barrett’s esophagus. Gastrointest Endosc. 2000;52:328–332
  68. Mino-Kenudson M, Brugge WR, Puricelli WP, et al. Management of superficial Barrett’s epithelium-related neoplasms by endoscopic mucosal resection. Am J Surg Pathol. 2005;29:680–686
  69. Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett’s epithelium: A new approach to management of Barrett’s esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc. 2003;57:854–859
  70. Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium. Gastroenterology. 1993;104:1686–1691
  71. Gossner L, May A, Stolte M, et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett’s esophagus. Gastrointest Endosc. 1999;49:8–12
  72. Sharma P, Jaffe PE, Bhattacharyya A, et al. Laser and multipolar electrocoagulation ablation of early Barrett’s adenocarcinoma: Long-term follow-up. Gastrointest Endosc. 1999;49:442–446
  73. Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett’s high grade dysplasia and early adenocarcinoma. Am J Gastroenterol. 2002;97:2998–3006
  74. Kovacs BJ, Chen YK, Lewis TD, et al. Successful reversal of Barrett’s esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc. 1999;49:547–553
  75. Montes CG, Brandalise NA, Deliza R, et al. Antireflux surgery followed by bipolar electrocoagulation in the treatment of Barrett’s esophagus. Gastrointest Endosc. 1999;50:173–177
  76. Sharma P, Bhattacharyya A, Garewal HS, et al. Durability of new squamous epithelium after endoscopic reversal of Barrett’s esophagus. Gastrointest Endosc. 1999;50:159–164
  77. Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett’s esophagus with thermal electrocoagulation combined with high-dose acid inhibition: A multicenter study. Gastrointest Endosc. 2001;53:554–558
  78. Eisen GM. Ablation therapy for Barrett’s esophagus. Gastrointest Endosc. 2003;58:760–769
  79. Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett’s epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc. 2000;51:659–663
  80. Madisch A, Miehlke S, Bayerdoerffer E, et al. Long-term follow-up after complete ablation of Barrett’s esophagus with argon plasma coagulation. World J Gastroenterol. 2005;11:1182–1186
  81. Ganz RA, Utley DS, Stern RA, et al. Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: A phased evaluation in the porcine and in the human esophagus. Gastrointest Endosc. 2004;60:1002–1010
  82. Dunkin BJ, Martinez J, Bejarano PA, et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endosc. 2006;20:125–130
  83. Johnston MH, Schoenfeld P, Mysore JV, et al. Endoscopic spray cryotherapy: A new technique for mucosal ablation in the esophagus. Gastrointest Endosc. 1999;50:86–92
  84. Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett’s esophagus: A pilot study. Gastrointest Endosc. 2005;62:842–848
  85. Overholt B, Panjehpour M, Tefftellar E, et al. Photodynamic therapy for treatment of early adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 1993;39:73–76
  86. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: International, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–498
  87. Overholt BF, Panjehpour M. Barrett’s esophagus: Photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc. 1995;42:64–70
  88. Laukka MA, Wang KK. Initial results using low-dose photodynamic therapy in the treatment of Barrett’s esophagus. Gastrointest Endosc. 1995;42:59–63
  89. Barr H, Krasner N, Boulos PB, et al. Photodynamic therapy for colorectal cancer: A quantitative pilot study. Br J Surg. 1990;77:93–96
  90. Heier SK, Rothman KA, Heier LM, Rosenthal WS. Photodynamic therapy for obstructing esophageal cancer: Light dosimetry and randomized comparison with Nd:YAG laser therapy. Gastroenterology. 1995;109:63–72
  91. Lovat LB, Jamieson NF, Novelli MR, et al. Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett’s columnar lined esophagus. Gastrointest Endosc. 2005;62:617–623
  92. Javaid B, Watt P, Krasner N. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): A preliminary study. Lasers Med Sci. 2002;17:51–56
  93. Etienne J, Dorme N, Bourg-Heckly G, et al. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorin for intramucosal adenocarcinoma and high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2004;59:880–889
  94. Wolfsen HC, Ng CS. Cutaneous consequences of photodynamic therapy. Cutis. 2002;69:140–142
  95. Wang KK, Nijhawan PK. Complications of photodynamic therapy in gastrointestinal disease. Gastrointest Endosc Clin North Am. 2000;10:487–495
  96. Behrens A, May A, Gossner L, et al. Curative treatment for high-grade intraepithelial neoplasia in Barrett’s esophagus. Endoscopy. 2005;37:999–1005
  97. Tan WC, Fulljames C, Stone N, et al. Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett’s metaplasia. J Photochem Photobiol B. 1999;53:75–80
  98. Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: A randomised trial. Gut. 2004;53:785–790
  99. Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett’s oesophagus: A prospective, double blind, randomised, placebo controlled trial. Gut. 2000;47:612–617
  100. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc. 2005;62:24–30
  101. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc. 2003;58:183–188
  102. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett’s esophagus with high grade dysplasia. Dig Dis Sci. 2003;48:1273–1283
  103. Vij R, Triadafilopoulos G, Owens DK, et al. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2004;60:739–756
  104. Shaheen NJ, Inadomi JM, Overholt BF, et al. What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? (A cost effectiveness analysis). Gut. 2004;53:1736–1744
  105. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol. 2002;14:1085–1091
  106. Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett’s esophagus. Gastrointest Endosc. 2001;54:682–688
  107. Peters F, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett’s esophagus. Gastrointestinal Endoscopy. 2005;61:506–514
  108. Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett’s oesophagus: A randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004;20:1289–1296
  109. Ragunath K, Krasner N, Raman VS, et al. Endoscopic ablation of dysplastic Barrett’s oesophagus comparing argon plasma coagulation and photodynamic therapy: A randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005;40:750–758
  110. Pacifico RJ, Wang KK, Wongkeesong LM, et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2003;1:252–257
  111. Barr H, Shepherd NA, Dix A, et al. Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348:584–585
  112. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc. 2002;77:1176–1181
  113. Panjehpour M, Overholt BF, Haydek JM, et al. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett’s esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol. 2000;95:2177–2184
  114. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998;114:448–455
  115. Foroulis CN, Thorpe JA. Photodynamic therapy (PDT) in Barrett’s esophagus with dysplasia or early cancer. Eur J Cardiothorac Surg. 2006;29:30–34

PII: S1053-4296(06)00069-5

doi: 10.1016/j.semradonc.2006.09.004

Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 10-21 , January 2007

Article Tools

* Image Usage & Resolution